Not a good buy right now for an impatient buyer: momentum is weakening short-term (MACD positive but contracting, RSI 43) and price is below the pivot (24.82).
Options positioning leans defensive (OI put-call ratio 1.43) while insider selling has accelerated (+420.71% last month), which is a near-term red flag.
Bullish longer-term structure remains (SMA_5 > SMA_20 > SMA_200) and Wall Street upside is large after the recent upgrade, but the best setup would be after reclaiming ~24.82 pivot or holding support ~23.39.
Trend/structure: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the broader trend is constructive.
Momentum: MACD histogram is above zero (0.0734) but positively contracting → upside momentum is fading rather than accelerating.
RSI (6): 42.6 (neutral-to-soft) → not oversold; no strong “snap-back” buy signal.
Key levels: Pivot 24.824 (price 23.97 is below), Support S1 23.387 then S2 22.50; Resistance R1 26.26 then R2 27.147.
Practical read: Near-term bias is cautious unless price reclaims ~24.82; losing ~23.39 increases risk of a pullback toward ~22.50.
Pattern-based forecast provided: ~70% chance of +0.06% next day, +2.79% next week, +9.64% next month (mild positive skew, but not a strong “must-buy now” signal).
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Open interest put-call ratio at 1.43 implies more puts than calls outstanding → moderately bearish/hedged positioning.
Volume: Very low options activity today (total volume 2; put volume 0), so intraday options sentiment is not very informative.
Volatility: Implied vol (30d) ~102.7 vs historical vol ~79.4 → options are pricing elevated uncertainty; IV rank ~30.8 / IV percentile ~32.9 (not extreme, but still high absolute IV).
Takeaway: Options market is positioned more defensively via open interest, consistent with “not an urgent buy today.”
Technical Summary
Sell
7
Buy
5
Positive Catalysts
Analyst sentiment improved sharply: H.C. Wainwright upgraded to Buy and raised PT to $45 (from $20), citing increased conviction and encouraging colorectal cancer view.
No negative headline flow in the last week (no fresh bad news catalyst showing up in the provided feed).
Neutral/Negative Catalysts
suggests hedging/defensive posture.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $15K, down -55.88% YoY (very weak top-line trend).
Net income: -38.846M, down -12.87% YoY (still deeply loss-making).
EPS: -2.13, down -38.79% YoY (loss per share widened).
Gross margin: 100% (typical artifact for very low revenue; not the key driver here).
Growth read: Financials reflect a pre-commercial biotech profile with ongoing burn; price action will likely be more catalyst/data-driven than fundamentals-driven in the near term.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: 2025-12-09 H.C. Wainwright upgraded LYEL to Buy from Neutral and lifted PT to $45 (from $20), citing stronger conviction after data/KOL feedback and positioning in CAR-T durability.
Prior stance: 2025-11-24 H.C. Wainwright kept Neutral but raised PT to $20 (from $10), adding colorectal cancer to valuation.
Wall Street pros view: Significant upside implied by the new $45 target and improved confidence in clinical durability narrative.
Wall Street cons view: Earlier Neutral rating indicates prior skepticism; with limited financial traction, the bull case remains heavily dependent on clinical execution and future catalysts rather than operating results.
Influential/political trading: No recent congress trading data available; hedge funds shown as neutral in the last quarter.
Wall Street analysts forecast LYEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 28.5 USD with a low forecast of 12 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LYEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 28.5 USD with a low forecast of 12 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
1 Sell
Hold
Current: 22.640
Low
12
Averages
28.5
High
45
Current: 22.640
Low
12
Averages
28.5
High
45
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$20 -> $45
AI Analysis
2025-12-09
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20 -> $45
AI Analysis
2025-12-09
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Lyell Immunopharma to Buy from Neutral with a price target of $45, up from $20. The firm has "increased conviction" following the company's recent data and a key opinion leader call on colorectal cancer. Ronde-cel has established itself as the "durability leader in the CD19/CD20 CAR-T race," the analyst tells investors in a research note. H.C. Wainwright adds that its new expert feedback confirms that Lyell's existing LYL273 dataset is "already clearing the clinical high jump for success" in third and fourth lines colorectal cancer "by a wide margin."
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$10 -> $20
2025-11-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $20
2025-11-24
maintain
Neutral
Reason
H.C. Wainwright raised the firm's price target on Lyell Immunopharma to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company's valuation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LYEL
